Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool–Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists

British Journal of Dermatology

Volumn 177, Issue 4, 2017, Pages 1086-1092

  Tiao, J ^a,b   Feng, R ^c   Berger, E M ^d   Brandsema, J F ^e   Coughlin, C C ^f   Khan, N ^a,b   Kichula, E A ^e   Lerman, M A ^e   Lvovich, S ^g   McMahon, P J ^e   Rider, L G ⁱ   Rubin, A I ^a,e   Scalzi, L V ^j   Smith, D M ^e   Taxter, A J ^h   Treat, J R ^e   Williams, R P ^k   Yum, S W ^e   Okawa, J ^a   Werth, V P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^h WAKE FOREST BAPTIST HEALTH   (United States)

ⁱ NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^j PENN STATE CHILDREN S HOSPITAL   (United States)

^k Minneapolis Clinic of Neurology   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONSTRUCT VALIDITY; CUTANEOUS ASSESSMENT TOOL BINARY METHOD; CUTANEOUS DERMATOMYOSITIS DISEASE AREA AND SEVERITY INDEX; DERMATOLOGIST; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTERRATER RELIABILITY; INTRARATER RELIABILITY; JUVENILE DERMATOMYOSITIS; MALE; NEUROLOGIST; PRIORITY JOURNAL; QUESTIONNAIRE; RELIABILITY; RHEUMATOLOGIST; SCHOOL CHILD; SCORING SYSTEM; COMPARATIVE STUDY; DERMATOMYOSITIS; EVALUATION STUDY; OBSERVER VARIATION; PHYSICAL EXAMINATION; PROCEDURES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

CHILD; DERMATOLOGISTS; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; NEUROLOGISTS; OBSERVER VARIATION; PHYSICAL EXAMINATION; RHEUMATOLOGISTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 85026465051     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15596     Document Type: Article

References (21)

1. Iorizzo LJ, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol 2008; 59:99–112.
2. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371:2201–12.
3. Mendez EP, Lipton R, Ramsey-Goldman R et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49:300–5.
4. Pachman LM, Hayford JR, Chung A et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25:1198–204.
5. Smith RL, Sundberg J, Shamiyah E et al. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004; 31:1644–9.
6. Bode RK, Klein-Gitelman MS, Miller ML et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49:7–15.
7. Huber AM, Lang B, LeBlanc CM et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43:541–9.
8. Christen-Zaech S, Seshadri R, Sundberg J et al. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58:571–6.
9. Almeida B, Campanilho-Marques R, Arnold K et al. Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated. Arthritis Rheumatol 2015; 67:2495–502.
10. Pilkington C. Clinical assessment in juvenile idiopathic inflammatory myopathies and the development of disease activity and damage tools. Curr Opin Rheumatol 2004; 16:673–7.
11. Campanilho-Marques R, Almeida B, Deakin C et al. Comparison of the utility and validity of three scoring tools to measure skin involvement in patients with juvenile dermatomyositis. Arthritis Care Res 2016; 68:1514–21.
12. Rider LG, Werth VP, Huber AM et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis. Arthritis Care Res 2011; 63(Suppl. 11):S118–57.
13. Huber AM, Dugan EM, Lachenbruch PA et al. The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2007; 46:1606–11.
14. Huber AM, Dugan EM, Lachenbruch PA et al. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum 2008; 59:214–21.
15. Huber AM, Lachenbruch PA, Dugan EM et al. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. Arthritis Rheum 2008; 59:352–6.
16. Goreshi R, Okawa J, Rose M et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dermatol 2012; 132:1117–24.
17. Klein RQ, Bangert CA, Costner M et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008; 159:887–94.
18. Yassaee M, Fiorentino D, Okawa J et al. Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument. Br J Dermatol 2010; 162:669–73.
19. Shoukri MM. Measures of interobserver agreement and reliability, 2nd edn. Boca Raton, FL: Chapman & Hall/CRC Press, 2010.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159–74.
21. Anyanwu CO, Fiorentino DF, Chung L et al. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI): characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol 2015; 173:969–74.